Full-Time

Group Leader

Immunology

Confirmed live in the last 24 hours

NewLimit

NewLimit

11-50 employees

Medicines for healthspan extension via epigenetics

Biotechnology
Healthcare

Senior

San Bruno, CA, USA

Category
Computational Biology
Biology Lab & Research
Biology & Biotech

You match the following NewLimit's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Ph.D. in cell biology, immunology, or a related field or comparable industry experience
  • Experience leading a team and managing direct reports
  • Experience with therapeutics development, ideally leading a portion of a discovery or development process in an immunology, infectious disease, or inflammatory disease setting
  • Deep knowledge of immunology & lymphocyte biology
Responsibilities
  • Lead a team of Scientists and Research Associates to develop reprogramming therapies
  • Develop functional assays and pre-clinical models for inflammatory and infectious disease indications
  • Evaluate reprogramming payloads using functional assays & pre-clinical models to validate payloads, select leads, and progress pre-clinical candidates
  • Collaborate with our Single Cell Technology, Epigenetic Editing, and Predictive Modeling teams to design, build, and test reprogramming interventions
  • Contribute to NewLimit’s product development decisions, company-wide goals, and technology platform
  • Contribute to day-to-day execution alongside your team.
Desired Qualifications
  • Direct experience with T cell biology, including relevant functional assays, pre-clinical models, and experimental methods
  • Experience with in vivo nucleic acid delivery technologies
  • Experience with pooled screening and related functional genomics methods
  • Strong molecular biology foundations and experience designing transgenic constructs
  • Experience with iterative product development cycles (e.g. design-build-test-learn)
  • Knowledge of aging biology, computational biology, and machine learning

NewLimit develops medicines aimed at extending human healthspan by reprogramming aging cells' epigenomes. This involves changing the chemical modifications on DNA and histone proteins to restore youthful functions in old cells, focusing initially on rejuvenating the immune system and liver. The company uses advanced technologies like single-cell genomics and machine learning to identify aging markers and create interventions that reverse these changes. Unlike competitors, NewLimit's approach is centered on epigenetic reprogramming, targeting age-related diseases with the goal of creating a new class of medicines that enhance health during aging. The company serves the healthcare market, working with pharmaceutical companies and healthcare providers, and aims to transform aging by developing effective treatments.

Company Size

11-50

Company Stage

Series A

Total Funding

$38.9M

Headquarters

South San Francisco, California

Founded

2022

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased interest in epigenetic reprogramming boosts NewLimit's market potential.
  • Machine learning aids in identifying novel drug candidates for age-related diseases.
  • FDA's favorable stance on aging therapies accelerates NewLimit's market entry.

What critics are saying

  • Rapid biotech advancements could render NewLimit's technologies obsolete without continuous innovation.
  • Ethical concerns and regulatory scrutiny may delay product approvals.
  • Competition from similar biotech firms could impact NewLimit's market share.

What makes NewLimit unique

  • NewLimit focuses on epigenetic reprogramming to extend human healthspan.
  • The company uses single-cell genomics and machine learning for drug discovery.
  • NewLimit targets age-related diseases with unmet needs, like immune system and liver rejuvenation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Parental Leave

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
NewLimit
May 17th, 2023
NewLimit secures $40 million in venture funding from Dimension Capital, Founders Fund, Kleiner Perkins and other investors

NewLimit works across cell biology, genomics, machine learning, and cellular reprogramming to treat diseases and reverse aging

TechCrunch
May 16th, 2023
NewLimit, co-founded by Coinbase CEO Brian Armstrong, raises $40M to extend life

NewLimit aims to increase the number of healthy years each person lives by epigenetically reprogramming cells.

Fortune
May 16th, 2023
Coinbase's Armstrong gets $40M for anti-aging startup | Fortune Crypto

NewLimit, a startup that aspires to reverse aging by manipulating cells, announced on Tuesday that it’s raised $40 million in a Series A round from Kleiner Perkins and other venture firms, and from prominent individuals like former Google CEO Eric Schmidt and Y Combinator CEO Garry Tan.